In vitro activities of five new antimicrobial agents against Brucella melitensis

International Journal of Antimicrobial Agents

Volumn 12, Issue 2, 1999, Pages 185-186

  Trujillano Martin, I ^a   Garcia Sanchez, E ^a   Fresnadillo, M J ^a   Garcia Sanchez, J E ^a   Garcia Rodriguez, J A ^a   Montes Martinez, I ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; EPEREZOLID; LINEZOLID; PSEUDOMONIC ACID; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBACTERIAL ACTIVITY; BRUCELLA MELITENSIS; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

EID: 0033039676     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00049-7     Document Type: Letter

References (11)

1. R. Lang M. Banai M. Lishner E. Rubinstein Brucellosis Int. J. Antimicrob. Agents 5 1995 203 208
2. G. Acocella A. Bertrand J. Beytout J.B. Durrande J.A. Garcı́a-Rodrı́guez J. Kosmidis M. Micoud M. Rey M. Rodrı́guez Zapata J. Roux J.P. Stahl Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study J. Antimicrob. Chemother. 23 1990 433 439
3. Pechere JC. Streptogramins. A unique class of antibiotics. Drugs 1996;51 Suppl.1:13–19.
4. Finch RG. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs 1996;51 Suppl 1:31–37.
5. G.M. Eliopoulos C.B. Wennersten H.S. Gold R.C. Moellering Jr. In vitro activities of new oxazolidinone antimicrobials against enterococci Antimicrob. Agents Chemother. 40 1996 1745 1747
6. A. Ward D.M. Campoli-Richards Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use Drugs 32 1986 425 444
7. M.W. Casewell R.L.R. Hill Elimination of nasal carriage of Staphylococcus aureus with mupirocin (pseudomonic acid)—a controlled trial Antimicrob. Agents Chemother. 17 1986 365 372
8. S.P. Klemens M.A. Grossi M.H. Cynamon Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex Antimicrob. Agents Chemother. 38 1994 234 237
9. R.J. O'Brien M.A. Lyle D.E. Snider Jr. Rifabutin (Ansamycin LM 427): a new rifamycin S derivative for the treatment of mycobacterial diseases Rev. Infect. Dis. 9 1987 519 530
10. J.A. Garcı́a-Rodrı́guez J.E. Garcı́a-Sánchez I. Trujillano Lack of effective bactericidal activity of new quinolones against Brucella spp Antimicrob. Agents Chemother. 35 1991 756 759
11. P.K. Narang Clinical pharmacology of rifabutin: a new amtimycobacterial Rev. Contemp. Pharmacother. 6 1995 129 151